<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35395244</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>03</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>03</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1879-0631</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>299</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>Life sciences</Title>
          <ISOAbbreviation>Life Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Intranasal metformin treatment ameliorates cognitive functions via insulin signaling pathway in ICV-STZ-induced mice model of Alzheimer's disease.</ArticleTitle>
        <Pagination>
          <StartPage>120538</StartPage>
          <MedlinePgn>120538</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.lfs.2022.120538</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0024-3205(22)00238-7</ELocationID>
        <Abstract>
          <AbstractText Label="AIMS" NlmCategory="OBJECTIVE">The relationship between type 2 diabetes and Alzheimer's disease (AD) provides evidence that insulin and insulin sensitizers may be beneficial for the treatment of AD. The present study investigated the effect and mechanism of action of intranasal metformin treatment on impaired cognitive functions in an experimental mice model of AD.</AbstractText>
          <AbstractText Label="MAIN METHODS" NlmCategory="METHODS">Intracerebroventricularly (ICV) streptozotocin (STZ)-injected mice were treated with intranasal or oral metformin for 4 weeks. Learning and memory functions were evaluated using Morris water maze. Metformin and Aβ42 concentrations were determined by liquid chromatography tandem mass spectrometry and ELISA respectively. The expressions of insulin receptor, Akt and their phosphorylated forms were determined in the hippocampi and cerebral cortices of mice.</AbstractText>
          <AbstractText Label="KEY FINDINGS" NlmCategory="RESULTS">ICV-STZ-induced AD mice displayed impaired learning and memory functions which were improved by metformin treatment. ICV-STZ injection or intranasal/oral metformin treatments had no effect on blood glucose concentrations. Intranasal treatment yielded higher concentration of metformin in the hippocampus and lower in the plasma compared to oral treatment. ICV-STZ injection and metformin treatments did not change amyloid β-42 concentration in the hippocampus of mice. In hippocampal and cortical tissues of ICV-STZ-induced AD mice, insulin receptor (IR) and Akt expressions were unchanged, while phosphorylated insulin receptor (pIR) and pAkt expressions decreased compared to control. Metformin treatments did not change IR and Akt expressions but increased pIR and pAkt expressions.</AbstractText>
          <AbstractText Label="SIGNIFICANCE" NlmCategory="CONCLUSIONS">The present study showed for the first time that intranasal metformin treatment improved the impaired cognitive functions through increasing insulin sensitivity in ICV-STZ-induced mice model of AD.</AbstractText>
          <CopyrightInformation>Copyright © 2022 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Kazkayasi</LastName>
            <ForeName>Inci</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Hacettepe University, Faculty of Pharmacy, Department of Pharmacology, Ankara, Turkey. Electronic address: inci.kazkayasi@hacettepe.edu.tr.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Telli</LastName>
            <ForeName>Gokcen</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Hacettepe University, Faculty of Pharmacy, Department of Pharmacology, Ankara, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nemutlu</LastName>
            <ForeName>Emirhan</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Hacettepe University, Faculty of Pharmacy, Department of Analytical Chemistry, Ankara, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Uma</LastName>
            <ForeName>Serdar</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Hacettepe University, Faculty of Pharmacy, Department of Pharmacology, Ankara, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>06</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Life Sci</MedlineTA>
        <NlmUniqueID>0375521</NlmUniqueID>
        <ISSNLinking>0024-3205</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007328">Insulin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>5W494URQ81</RegistryNumber>
          <NameOfSubstance UI="D013311">Streptozocin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9100L32L2N</RegistryNumber>
          <NameOfSubstance UI="D008687">Metformin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="D011972">Receptor, Insulin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007328" MajorTopicYN="N">Insulin</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008687" MajorTopicYN="Y">Metformin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011972" MajorTopicYN="N">Receptor, Insulin</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013311" MajorTopicYN="N">Streptozocin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Alzheimer's disease</Keyword>
        <Keyword MajorTopicYN="N">Brain insulin resistance</Keyword>
        <Keyword MajorTopicYN="N">Diabetes</Keyword>
        <Keyword MajorTopicYN="N">Insulin signaling</Keyword>
        <Keyword MajorTopicYN="N">Intranasal</Keyword>
        <Keyword MajorTopicYN="N">Learning and memory</Keyword>
        <Keyword MajorTopicYN="N">Metformin</Keyword>
        <Keyword MajorTopicYN="N">Type 3 diabetes</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>8</Day>
          <Hour>20</Hour>
          <Minute>9</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35395244</ArticleId>
        <ArticleId IdType="doi">10.1016/j.lfs.2022.120538</ArticleId>
        <ArticleId IdType="pii">S0024-3205(22)00238-7</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
